ACTH stimulation test

ACTH stimulation test. This diagnostic procedure is a cornerstone in the evaluation of the hypothalamic-pituitary-adrenal axis, primarily used to assess adrenal gland function. It involves the administration of synthetic adrenocorticotropic hormone to measure the adrenal cortex's ability to produce cortisol in response. The test is critical for diagnosing conditions such as Addison's disease, secondary adrenal insufficiency, and in some protocols for congenital adrenal hyperplasia.

Indications and uses

The primary indication is the investigation of suspected adrenal insufficiency, whether primary as in Addison's disease or secondary due to pituitary gland dysfunction. It is employed in the diagnostic workup for conditions like Cushing's syndrome when differentiating its various etiologies. The test is also utilized to assess adrenal reserve in patients with a history of chronic glucocorticoid therapy or following pituitary surgery for tumors such as a pituitary adenoma. Furthermore, it plays a role in evaluating the response of certain adrenal tumors and is a component of diagnostic protocols established by institutions like the Mayo Clinic and the National Institutes of Health.

Procedure

The test is typically performed in the morning to account for circadian rhythm influences on cortisol levels. A baseline blood sample is drawn to measure cortisol and sometimes aldosterone. Then, a dose of synthetic cosyntropin, which is analogous to adrenocorticotropic hormone, is administered either intravenously or intramuscularly. Subsequent blood samples are collected at specific intervals, commonly 30 and 60 minutes after the injection, to measure the adrenal gland's secretory response. The entire process is usually conducted in an outpatient setting under the supervision of an endocrinologist or trained staff at a hospital or clinic.

Interpretation of results

A normal response is characterized by a rise in serum cortisol to a peak level above a specific threshold, often 18-20 μg/dL, demonstrating adequate adrenal reserve. A subnormal response indicates adrenal insufficiency; in primary cases like Addison's disease, both cortisol and aldosterone responses are typically blunted. For suspected secondary adrenal insufficiency due to pituitary disease, a low-dose variant of the test may be employed for greater sensitivity. Interpretation must always consider the assay methods used by laboratories such as Quest Diagnostics and the clinical context, including medications that may interfere.

Limitations and considerations

The standard test using cosyntropin may not detect recent-onset secondary adrenal insufficiency, as the adrenal gland may not have atrophied sufficiently. False-normal results can occur, particularly following a recent pituitary apoplexy. Certain medications, including ketoconazole and phenytoin, can affect results. The test does not differentiate between all causes of Cushing's syndrome and is generally not used in isolation for that diagnosis. Considerations for patient safety include monitoring for potential allergic reactions to cosyntropin, though such events are rare.

History and development

The physiological basis stems from the work of early endocrinologists like Harvey Cushing, who described the pituitary gland's role. The concept of stimulating the adrenal cortex with pituitary extracts was explored in the mid-20th century. The modern test was refined following the synthesis of cosyntropin in the 1960s, providing a standardized and safer stimulus than animal-derived ACTH. Its diagnostic criteria and protocols have been evolved through research conducted at major institutions like the Cleveland Clinic and endorsed by professional societies such as the Endocrine Society.

Category:Medical tests Category:Endocrinology